[Joe]

We wanted to share with you that GSK’s ALTTO clinical trial is currently open for enrollment and is seeking patients. You may have seen a press release from the National Cancer Institute (NCI), North Central Cancer Treatment Group (NCCTG) and Breast International Group (BIG) announcing the trial today.The ALTTO trial (The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial) is an international phase III clinical trial that will examine the role of two HER2 directed therapies in the treatment of early stage, HER2 positive breast cancer. The ALTTO trial is one of the largest clinical trials ever conducted in breast cancer and represents an exciting step as researchers investigate the potential of these therapies in early breast cancer.The Breast International Group (BIG) and the North Central Cancer Treatment Group (NCTTG) together are conducting enrollment in the <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-comffice:smarttags" /><st1lace w:st="on"><st1:country-region w:st="on">U.S.</st1:country-region></st1lace> and abroad with a target enrollment of 8,000 patients worldwide. The following information resources are available for more details about ALTTO, including eligibility and registration criteria:


--Visit www.clinicaltrials.gov, keyword ALTTO or www.alttotrials.com
--Breast International Group (BIG): Web site: www.breastinternationalgroup.org or
e-mail: ALTTOtrials@bordet.be
--North Central Cancer Treatment Group (NCCTG): e-mail: ncctg@mayo.edu
--GlaxoSmithKline: e-mail: lapatinibtrials.northamerica@gsk.com